

Table S8. Proliferative index for all included samples with RNAseq data, in addition to other sample information.

Patient_ID	Diagnosis	Progression	Progression	Progression	Progression	PI Change [§]	TBS	PFS	2nd sample	1st progression	Ig-T/HRD	CCND1 exp	CCND2 exp	Cyto risk [§]	Risk status	Progression <2 y	Progression <1 y	dead	TTD	
65		1.0	3.9			2.93	22	19		yes	HRD	MH	N	HR	yes	no	y	0		
63		1.9	4.7			2.79	15	3		no	t(8;14)	N	MH	HR (del17)	HR	yes	no*	y	3	
27		1.5	5.5	4.0		2.50	17/2	17		yes	t(4;14)	N	MH	HR (t(4;14))	HR	yes	no	y	1	
31		1.1	2.0	3.1		2.05	14/5	12		yes	t(4;14)	N	L	HR (t(4;14))	HR	yes	no	y	1	
20		1.9	4.2			2.32	50	13		no	t(11;14)	VH	N		HR	no*	no	y	2	
60		1.5	4.2			2.65	18	11		no	HRD	MH	N	SR	yes	no*	y	0		
28		1.9	4.5			2.61	9	9		yes	HRD	N	L	SR	yes	yes	y	19		
46		1.9	4.3			2.47	18	7		no	unknown	MH	VH	SR	yes	no*	y	3		
51		1.1	3.2			2.09	18	9		no	HRD	MH	L	SR	yes	no*	y	1		
49		1.6	3.6			2.02	18	10		no	HRD	MH	N	SR	yes	no*	y	0		
55		0.8	2.3			1.48	18	17		yes	HRD	N	MH	SR	yes	no	n	>41		
58		2.5	3.9			1.41	9	8		yes	HRD	N	MH	SR	yes	yes	y	4		
50		1.5	2.9			1.45	36	2		no	t(11;14)	VH	N	SR	no*	no*	n	>29		
52		1.4	4.4			3.06	39	36		no	HRD	L	N	SR	no	no	n	>27		
54		1.8	3.4			1.53	33	32		yes	t(6;14)	N	N**	SR	no	no	n	>13		
53		0.6	2.1			1.52	42	42		yes	HRD	MH	N	SR	no	no	n	>25		
18		2.3	2.3	3.7		1.35	17/14	16		yes	HRD	N	MH	SR	yes	no	y	0		
10		1.8	3.0			1.21	16	11		yes	t(4;14)	N	MH	HR (t(4;14))	HR	yes	no	y	19	
24		0.3	1.4			1.07	24	2		no	t(11;14)	MH	N	HR	yes	no*	y	10		
15		1.4	1.6	2.3		0.90	48/13	45		yes	HRD	MH	N	HR (t(4;14))	HR	no	no	y	46	
26		2.51	2.13	3.28		0.78	14/6	13		yes	HRD	N	MH	HR	yes	no	y	1		
34		2.5	2.7	3.5	3.3	0.75	9/7	7		no	HRD	N	N	SR	no	no	y	2		
32		0.2	0.9			0.69	18	18		yes	HRD	L	N	SR	yes	no	y	1		
42		1.3	1.9			0.65	30	26		yes	HRD	N	L	SR	no	no	y	38		
23		0.5	0.4	1.1		0.52	25/38	25		yes	HRD	L	N	SR	no	no	y	14		
8		1.3	1.8			0.49	9	-		no	t(11;14)	VH	N	SR	no	no	y	4		
25		0.3	0.8	0.8		0.49	16/23	9		no	HRD	L	N	SR	yes	no	y	27		
47		1.8	2.2			0.42	21	19		yes	t(4;14)	N	MH	HR (t(4;14))	HR	yes	no	y	31	
61		2.9	3.2			0.34	15	15		yes	t(11;14)	VH	N	HR (del17)	HR	yes	no	y	21	
59		1.0	1.3			0.31	18	11		no	t(4;14)	N	MH	HR (t(4;14))	HR	yes	no	n	>43	
4		1.7	1.9			0.28	39	21		no	t(11;14)	VH	N	HR	no*	no	y	6		
9		1.0	1.2			0.25	38	27		no	t(11;14)	VH	N	SR	no	no	n	>46		
43		1.1	1.6	1.3		0.24	30/21	29		yes	t(4;14)	N	MH	HR (t(4;14))	HR	no	no	y	21	
48		1.7	1.8			0.18	18	17		yes	HRD	N	MH	SR	yes	no	y	5		
30		0.5	0.6			0.15	12	11		yes	HRD	L	N	SR	yes	yes	n	>47		
45		1.3	1.4			0.10	36	37		yes	t(11;14)	VH	N	SR	no	no	n	>7		
29		0.5	0.5			-0.01	5	5		yes	HRD	L	N	SR	yes	yes	y	20		
33		0.9	0.9			-0.06	18	16		yes	t(11;14)	VH	N	SR	yes	no	y	22		
35		1.0	0.9			-0.07	24	-		no	HRD	L	N	SR	no	no	y	26		
40		1.7	1.6	1.2	1.7	-0.07	21/12/21	18		yes	t(11;14)	VH	N	SR	yes	no	n	>18		
66		2.2	1.9			-0.29	21	7		no	HRD	MH	MH	SR	yes	no*	y	19		
36		1.50	1.12			-0.38	36	-		no	HRD	L	N	SR	no	no	y	48		
67		1.2	0.8			-0.42	18	19		no	HRD	N	L	SR	yes	no	n	>32		
44		2.3	1.8			-0.48	45	5		no	t(11;14)	VH	N	SR	no*	no*	n	22		
57		2.2	1.7			-0.53	27	26		yes	t(12;14)	N	VH	SR	no	no	n	>36		
62		2.1	1.5			-0.56	27	21		no	t(4;14)	L	VH	HR (t(4;14))	HR	no*	no	y	6	
41		1.6	1.1			-0.57	36	18		no	t(4;14)	L	L	HR (t(4;14))	HR	no*	no	y	29	
56		2.5	1.1			-1.33	15	15		yes	t(11;14)	VH	N	SR	yes	no	n	>36		
64		3.6	1.7			-1.95	3	3		yes	t(4;14)	N	MH	HR (t(4;14))	HR	yes	yes	y	10	

[§] change in PI (Proliferative Index; see methods) from first to last sample. Bold=change >0.4.

[§] Cytogenetic risk: High Risk (HR); t(4;14), t(14;16) or del17p detected by FISH (in-house cohort) or canonical translocation from long insert WGS (CoMMpass)

Ig-T/HRD: Cytogenetic subgroup, includes t(11;14)/CCND1, t(12;14)/ CCND2, t(6;14)/CCND3, t(4;14)/WHSC1(NSD2/MMSET), t(8;14)/MAFA (see Supplementary Table 12).

Risk status: HR: R-ISS 3 (or if not available, ISS 3), SR: Not HR

PFS: Time to first progression (from diagnosis). Only included for diagnosis-progression patients.

TTD = Time To Death or Time To Last Control (if still alive) from last sample.

TBS: Time between samples (months). If more than 2 samples, "/" are used to separate samples pairs, i.e S1-S2/S2-S3

CCND1/2 exp: Expression of CCND1/2 at diagnosis. N: No expression (TPM<2), L: Low (TPM 2-20), MH: Medium high (TPM 20-100), VH: Very high (TPM>100).

Relapse < 2y; yes: relapse within 24 months from diagnosis, if not: no. For patients with many relapses, first sample are used for this definition. *Patient has progressed within 24 months but no BM sample available for that time

Relapse < 1y; yes: relapse within 12 months from diagnosis, if not: no. For patients with many relapses, first sample are used for this definition. *Patient has progressed within 12 months but no BM sample available for that time